06.02.16
A clinical study published in the British Journal of Nutrition confirmed the benefits of Lacidofil probiotic formula (Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52) in the management of antibiotic-associated diarrhea (AAD). In the study, the ADD episodes were reduced by 24 hours on average. Lacidofil is Lallemand Health Solutions flagship probiotic formula, supported by 26 clinical trials altogether in children and adults, corresponding to over 1,700 patients enrolled. Marketed for over two decades in many countries, in some of them with a drug status, Lacidofil benefits from a pharmacovigilance program demonstrating safety of use.
The randomized double-blind, placebo controlled trial conducted in Canada involved 146 healthy adults. The subjects received a broad spectrum antibiotic treatment (amoxicillin-clavulanic acid) for one week in addition to the probiotic or placebo, followed by one week of probiotic alone. Patients were followed-up for up to nine weeks after the beginning of the treatment. It was shown that, on average, participants supplemented with the probiotic experienced significantly shorter duration of diarrhea-like defecations events compared with those taking the placebo (see graph): 2.70 ± 0.36 days, compared to 3.71 ± 0.36 days for the placebo group (p = 0.037).
According to the authors, “decreasing the number of days of diarrhoea after antibiotic treatment has clinical relevance, as it may reduce complications related to AAD. This is particularly important among patients who are more susceptible to severe AAD, as well as in attenuating the symptoms of AAD in individuals with a healthy digestive system receiving antibiotics for infections outside the gut.” Moreover, this is the first study to demonstrate this beneficial effect with probiotics on AAD in a population of healthy adults.
Genetic analysis performed on the fecal samples collected all along this study enabled researchers to detect and quantify the probiotic strains Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52. It appeared that both probiotic strains survived the intestinal tract when administered concomitantly with the antibiotic, confirming the compatibility of Lacidofil with broad spectrum antibiotic treatment amoxicillin-clavulanic acid.
This new study comes to strengthen previous studies specifically in ADD with Lacidofil conducted in adults ( three studies) and children (seven studies), indicating consistently alleviation of AAD symptoms in patients.
For more information: www.lallemand-health-solutions.com
The randomized double-blind, placebo controlled trial conducted in Canada involved 146 healthy adults. The subjects received a broad spectrum antibiotic treatment (amoxicillin-clavulanic acid) for one week in addition to the probiotic or placebo, followed by one week of probiotic alone. Patients were followed-up for up to nine weeks after the beginning of the treatment. It was shown that, on average, participants supplemented with the probiotic experienced significantly shorter duration of diarrhea-like defecations events compared with those taking the placebo (see graph): 2.70 ± 0.36 days, compared to 3.71 ± 0.36 days for the placebo group (p = 0.037).
According to the authors, “decreasing the number of days of diarrhoea after antibiotic treatment has clinical relevance, as it may reduce complications related to AAD. This is particularly important among patients who are more susceptible to severe AAD, as well as in attenuating the symptoms of AAD in individuals with a healthy digestive system receiving antibiotics for infections outside the gut.” Moreover, this is the first study to demonstrate this beneficial effect with probiotics on AAD in a population of healthy adults.
Genetic analysis performed on the fecal samples collected all along this study enabled researchers to detect and quantify the probiotic strains Lactobacillus rhamnosus Rosell-11 and Lactobacillus helveticus Rosell-52. It appeared that both probiotic strains survived the intestinal tract when administered concomitantly with the antibiotic, confirming the compatibility of Lacidofil with broad spectrum antibiotic treatment amoxicillin-clavulanic acid.
This new study comes to strengthen previous studies specifically in ADD with Lacidofil conducted in adults ( three studies) and children (seven studies), indicating consistently alleviation of AAD symptoms in patients.
For more information: www.lallemand-health-solutions.com
